These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9393221)

  • 41. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
    Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV disease progression in Australia in the time of combination antiretroviral therapies.
    Correll PK; Law MG; McDonald AM; Cooper DA; Kaldor JM
    Med J Aust; 1998 Nov; 169(9):469-72. PubMed ID: 9847898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
    Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
    AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group.
    Pezzotti P; Napoli PA; Acciai S; Boros S; Urciuoli R; Lazzeri V; Rezza G
    AIDS; 1999 Feb; 13(2):249-55. PubMed ID: 10202831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection.
    Girardi E; Antonucci G; Vanacore P; Libanore M; Errante I; Matteelli A; Ippolito G;
    AIDS; 2000 Sep; 14(13):1985-91. PubMed ID: 10997404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does pregnancy influence the course of HIV infection? Evidence from two large Swiss cohort studies.
    Weisser M; Rudin C; Battegay M; Pfluger D; Kully C; Egger M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(5):404-10. PubMed ID: 9562042
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts.
    Tarwater PM; Mellors J; Gore ME; Margolick JB; Phair J; Detels R; Muñoz A
    Am J Epidemiol; 2001 Oct; 154(7):675-81. PubMed ID: 11581102
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study.
    Furrer H; Opravil M; Bernasconi E; Telenti A; Egger M
    Lancet; 2000 Jun; 355(9222):2217-8. PubMed ID: 10881897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics.
    Ledergerber B; von Overbeck J; Egger M; Lüthy R
    Soz Praventivmed; 1994; 39(6):387-94. PubMed ID: 7817627
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival in HIV infection: do sex and category of transmission matter? Swiss HIV Cohort Study.
    von Overbeck J; Egger M; Smith GD; Schoep M; Ledergerber B; Furrer H; Malinverni R
    AIDS; 1994 Sep; 8(9):1307-13. PubMed ID: 7802985
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estimation of the temporal probability of human immunodeficiency virus (HIV) dementia after risk stratification for HIV-infected persons.
    Qureshi AI; Hanson DL; Jones JL; Janssen RS
    Neurology; 1998 Feb; 50(2):392-7. PubMed ID: 9484360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting outcomes in HIV-infected veterans: I. Progression to AIDS.
    Rabeneck L; Hartigan PM; Huang IW; Souchek J; Wray NP
    J Clin Epidemiol; 1997 Nov; 50(11):1231-40. PubMed ID: 9393379
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AIDS survival and progression in black Africans living in south London, 1986-1994.
    Low N; Paine K; Clark R; Mahalingam M; Pozniak AL
    Genitourin Med; 1996 Feb; 72(1):12-6. PubMed ID: 8655159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients.
    García de Olalla P; Knobel H; Carmona A; Guelar A; López-Colomés JL; Caylà JA
    J Acquir Immune Defic Syndr; 2002 May; 30(1):105-10. PubMed ID: 12048370
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidemiological composition, clinical and treatment characteristics of the patient cohort of the German Competence Network for HIV/AIDS.
    Jansen K; Brockmeyer NH; Hahn M; Kaul I; Fenske S; Rausch M; Kuhlmann B; Ulmer A; Lauenroth-Mai E; Harrer T; Hower M; Skaletz-Rorowski A; Michalik C;
    Eur J Med Res; 2009 Sep; 14(10):415-25. PubMed ID: 19748848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prevalence of pain in pediatric human immunodeficiency virus/acquired immunodeficiency syndrome as reported by participants in the Pediatric Late Outcomes Study (PACTG 219).
    Gaughan DM; Hughes MD; Seage GR; Selwyn PA; Carey VJ; Gortmaker SL; Oleske JM
    Pediatrics; 2002 Jun; 109(6):1144-52. PubMed ID: 12042556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.